This document announces a new, more appropriate, and systematic naming of newly emergent substance, MDA-19, and its related analogues that follows the systematic convention commonly used for synthetic cannabinoid nomenclature.
This brief document provides a purpose statement, background of synthetic cannabinoid substances along with the treatment of newly discovered variations, and a summary of the new naming convention for the emerging MDA-19 analogues and the OXIZID generation of synthetic cannabinoids. The document describes the molecular structure and the rationale for the application of the well-accepted systematic naming convention for synthetic cannabinoids, which will be applied to BZO-HEXOXIZID, BXO-POXIZID, and 5F-BZO-POXIZID. The document provides the chemical formula, names, synonyms, and a visual representation of each molecule. It also provides a listing of references and related articles.
Downloads
Similar Publications
- Substance use among women receiving post-rape medical care, associated post-assault concerns and current substance abuse: Results from a national telephone household probability sample
- Patterns of drug and alcohol use associated with lifetime sexual revictimization and current posttraumatic stress disorder among three national samples of adolescent, college, and household-residing women
- Potent Synthetic Opioid—Isotonitazene—Recently Identified in the Midwestern United States